变应性鼻结膜炎的变应原免疫疗法：一项系统评价方案
Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review.
作者信息
Dhami Sangeeta, Nurmatov Ulugbek, Roberts Graham, Pfaar Oliver, Muraro Antonella, Ansotegui Ignacio J, Calderon Moises, Cingi Cemal, Demoly Pascal, Durham Stephen, van Wijk Ronald Gerth, Halken Susanne, Hamelmann Eckard, Hellings Peter, Jacobsen Lars, Knol Edward, Larenas-Linnemann Desiree, Lin Sandra, Maggina Vivian, Oude-Elberink Hanneke, Pajno Giovanni, Panwankar Ruby, Pastorello Elideanna, Pitsios Constantinos, Rotiroti Giuseppina, Timmermans Frans, Tsilochristou Olympia, Varga Eva-Maria, Wilkinson Jamie, Williams Andrew, Worm Margitta, Zhang Luo, Sheikh Aziz
机构信息
Evidence-Based Health Care Ltd, Edinburgh, UK.
Systematic Review at Decision Resources Group Abacus International, Bicester, UK.
出版信息
Clin Transl Allergy. 2016 Mar 22;6:12. doi: 10.1186/s13601-016-0099-6. eCollection 2016.
BACKGROUND
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis.
METHODS
We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised.
CONCLUSION
The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
背景
欧洲变态反应与临床免疫学会（EAACI）正在制定变应原免疫疗法（AIT）治疗变应性鼻结膜炎的EAACI指南。我们旨在严格评估AIT治疗变应性鼻结膜炎的有效性、成本效益和安全性。
方法
我们将进行一项系统评价，包括检索国际生物医学数据库，以获取已发表、正在进行和未发表的证据。将根据预先确定的纳入标准对研究进行独立筛选，并使用既定工具进行严格评价。将对数据进行描述性分析，并在可能且合适的情况下进行定量综合分析。
结论
本评价的结果将用于为EAACI的AIT指南制定建议提供依据。
Zotero 插件